Omeros Corp $13.98

down -0.07


25/7/2014 04:00 PM  |  NASDAQ : OMER  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get OMER Trend Analysis - it has outperformed the S&P 500 by 133%

Partner Headlines

  1. US Stock Futures Edge Higher Ahead Of Jobless Claims Data

    Benzinga
  2. Omeros Announces Proposed Public Offering of Common Stock

    Benzinga
  3. Benzinga's Top #PreMarket Gainers

    Benzinga
  4. Benzinga's Top #PreMarket Gainers

    Benzinga
  5. UPDATE: FDA Grants Orphan Drug Designation to Omeros' OMS721 for Complement-Mediated ...

    Benzinga
  6. Hearing Wedbush Names Omeros Top Pick for 2014; $32 PT

    Benzinga
  7. Omeros Announces FDA Accepts Omidria as Brand Name for OMS302

    Benzinga
  8. Omeros Announces Positive OMS721 Data in Model of Age-Related Macular Degeneration

    Benzinga
  9. Omeros Reports Positive OMS721 Data

    Benzinga
  10. Omeros Says FDA Has Agreed to Pediatric Study Plan for OMS302

    Benzinga
  11. Benzinga's Top Pre-Market Gainers

    Benzinga
  12. Shares Of Omeros Rocket Higher As Wedbush Lifts Target, Sees Near Tripling ...

    Benzinga
  13. FDA, EMA Accept OMS302 Marketing Applications for Review

    Benzinga
  14. Omeros Announces FDA Orphan Drug Designation for OMS824 for Huntington's ...

    Benzinga
  15. Omeros Initiates Phase 2 Clinical Trial with OMS824

    Benzinga
  16. Benzinga's Top Pre-Market Losers

    Benzinga
  17. Wedbush Reiterates Outperform Rating on Omeros on Potential Increased OMS3 ...

    Benzinga
  18. Morning Market Movers

    Benzinga
  19. Omeros Reports Additional Positive Results from Phase 1 OMS824 Clinical ...

    Benzinga
  20. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief ...

    Benzinga
  21. Shares of Omeros Bounce Over $5.40 Following Mid-Day Comments from MLV's ...

    Benzinga
  22. Omeros Submits NDA for OMS302, Wedbush Says Approval Could be 'Catalyst' ...

    Benzinga
  23. UPDATE: Canaccord Genuity Cuts PT to $13 on Omeros Corporation on Phase ...

    Benzinga
  24. Stocks To Watch For December 28, 2012

    Benzinga
  25. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE1 ...

    Benzinga
  26. Omeros Announces Promising Data from Phase 1 OMS824 Clinical Trial

    Benzinga
  27. Omeros Responds to Misleading Announcement Concerning Settlement with ...

    Benzinga
  28. Omeros' Ophthalmology Announces Clinical Trial Data

    Benzinga
  29. From Earlier: Investigational New Drug Application Cleared for Omeros' ...

    Benzinga
  30. Omeros Files Investigational New Drug Application for Lead Compound in ...

    Benzinga
  31. Mead Johnson Nutrition, DaVita Among Stocks Hitting 52-Week Highs Friday

    FoxBusiness
  32. Benzinga's Microcap Movers for Tuesday January 10, 2012

    Benzinga
Trading Center